Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: amdiii who wrote (579)	3/17/1998 8:26:00 PM
From: amdiii	Read Replies (2) \| Respond to of 965

"Centocor will assume responsibility for the defense of certain RETAVASE-related patent litigation initiated against Boehringer Mannheim by Genentech in the U.S.and Germany. The expenses of such litigation will be shared by Roche, subject to certain limitations. In addition, Centocor will be reimbursed for certain liabilities that could result from this litigation and, under certain circumstances, will be refunded some or all of the purchase price." This is from the 8-K filed by CNTO on 2-13-98. I would think that the suit filed today is simply adding CNTO to orginal litigation. In few words, this is old news and should not effect the share price.